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matrix of likely sample size based on these values ranged from 44 to 193 per group. 
Based on this DPP, a sample of 120 per group was selected as the sample size that 
would deliver clinically meaningful results. ConClusions: A DPP is useful in late 
phase research to define appropriate sample size where no data exist. It is important 
to note that DPP methods do not require significance testing, but the benefit is no 
need for a correction for multiple comparisons at the time of the final analysis.
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objeCtives: To assess 1) how network meta-analyses (NMAs) included within 
manufacturer submissions to the National Institute for Health and Care Excellence 
(NICE) have been criticised by its Evidence Review Groups (ERGs); 2) how some 
of these criticisms might be avoided in future submissions; and 3) the extent to 
which such avoidance might increase the likelihood of a new intervention being 
approved. Methods: We reviewed the ERG reports of all NICE technology appraisals 
published since January 2007 to identify those where the manufacturer’s submission 
included an NMA. Subsequently, all criticisms made by the ERG of such analyses 
were analysed to seek common themes; and assess how often any one type of 
criticism was associated with a rejection by NICE. Results: A total of 181 NICE 
technology appraisal reports were evaluated. These covered 243 separate interven-
tions, 83 (34%) of which were drugs for cancer. Overall 37–64% of submissions cited 
NMAs, of which 43–83% were criticised, with this proportion having increased over 
time. Avoidable criticisms related to flaws in the systematic review methodology 
used to identify relevant RCTs for the analysis; inappropriate pooling of data from 
heterogeneous studies; and use of suboptimal statistical approaches in conducting 
the NMA. Unavoidable criticisms related to the lack of RCTs available for competitor 
drugs in the population of interest. However, no association was found between 
flaws in the NMA and a decision by NICE not to approve the use of the intervention. 
Instead, such rejection was associated mainly with a lack of evidence of clinical 
efficacy or cost-effectiveness in the target population. ConClusions: Most criti-
cisms of NMAs could be avoided by a more rigorous and transparent approach to 
conducting and reporting the underlying systematic review and statistical analysis. 
However, rejection of submissions remains a considerable risk where the underly-
ing evidence is weak.
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objeCtives: German HTA agency requires evidence about the additional benefit of 
a new pharmaceutical versus an appropriate comparator as basis for price negotia-
tions. This is challenging when head-to-head studies (H2HS) or randomized placebo-
controlled trials (RPCTs) are missing and particularly in dermatology, where topical 
therapies in registration trials are usually compared to their individual vehicle. The 
aim of this research was to describe different approaches to assess the additional 
benefit of a new topical therapy under these limitations. Methods: For ingen-
olmebutate-gel (IMG) and the appropriate comparator diclofenac-hyaluronic-acid 
(DHA) bibliographic literature search was conducted for RCTs followed by sequential 
screening on H2HS, comparable endpoints, RPCTs, common bridge comparator, 
H2HS of vehicles alone, RPCTs of vehicles. The similarity of vehicles was assessed 
by comparison of efficacy and safety profile. The lack of H2HS demands to conduct 
the following approaches depending on the comparability of vehicles: 1. An adjusted 
indirect comparison due to Bucher 1997 (vehicles are placebo-like or adequately 
similar) 2. Linkage of direct comparisons due to Wells 2009 (possible when H2HS or 
RPCTs of vehicles are available) 3. Mixed treatment comparison (MTC) (prerequisites 
as mentioned for Bucher). Results: 5 RCTs for IMG versus 3 RCTs for DHA were 
identified with comparable endpoints. No RPCTs for topical therapies or for their 
vehicles, no H2HS of vehicles, no bridge comparator and no clear evidence for the 
adequate similarity of both vehicles could be detected. Therefore, the prerequisites 
of all available statistical methods are not met and cannot thoroughly be applied. 
Notwithstanding these limitations, Bucher (RR[95%KI]: 4.14[2.03;8.47]) and MTC both 
favor IMG significantly while Wells showed non-inferiority (RR[95%KI]: 0.8[2,03;8,47]) 
in the primary endpoint of IMG versus DHA. ConClusions: A definition of ade-
quate similarity for vehicles by German HTA agencies is needed to enable the use of 
methodologically sound indirect comparisons or MTCs in reimbursement dossiers.
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objeCtives: In health technology assessment, decisions about reimbursement 
of new health technologies are largely based on effectiveness estimates. These 
estimates are sometimes also used to predict the health-related quality of life 
outcomes, such as EQ-5D, as part of economic evaluation. However, sometimes 
these effectiveness estimates are not readily available. When many alternative 
instruments measuring these outcomes are being used (and are not all reported) 
or an extended follow-up time of clinical trials is needed to evaluate long-term 
endpoints (and drug development is at an early stage), data on relevant outcomes 
may be limited. The aim of this study was to develop methodology that would allow 
synthesis of all available evidence to assess interventions early and reduce uncer-
tainty around relevant outcomes. Methods: Bayesian multivariate meta-analysis 
both challenges and opportunities for industry. The changes in the DSM-5 criteria 
may translate into changes for how we go about developing medical products to 
treat psychiatric disorders, including ADHD. There will need to be an investment in 
research and education, and sponsors must examine the possibility of developing 
new endpoints and outcome assessments for use in clinical trials.
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objeCtives: In May 2013, the American Psychiatric Association released the fifth 
edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), a 
classification system for psychiatric conditions. DSM-5 brings significant changes 
to many diagnostic categories as compared to the previous edition. The objective 
of this review was to examine the changes in the Major Depressive Disorder (MDD) 
criteria and discuss the impact these changes may have for industry. Methods: 
A line-by-line review of the DSM-5 and DSM-IV criteria for MDD was undertaken. 
Significant changes were highlighted and discussed from the point of view of spon-
sors of clinical trials for psychopharmacologic agents being developed to treat 
MDD. Results: The primary symptom criterion for MDD remains unchanged, 
requiring five of nine symptoms, over a two-week period. The changes of note 
have to do with the differential diagnoses and specifiers. One change that received 
significant attention in the time leading up to the publication of DSM-5 was the 
elimination of the bereavement exclusion, which discounted bereavement after the 
loss a loved one within the first two months as part of the normal grief process. In 
terms of specifiers, a new addition in MDD is “with anxious distress,” referring to 
episodes of depression characterized by at least two of five symptoms of anxiety. 
DSM-5 notes that this is associated with “greater likelihood of treatment nonre-
sponse.” Therefore, this is a factor sponsors may wish to consider in developing their 
trial inclusion/exclusion criteria. ConClusions: The significant changes in DSM-5 
pose both challenges and opportunities for industry. The changes in the DSM-5 
criteria translate into changes for how we go about developing medical products to 
treat psychiatric disorders, including MDD. There will need to be an investment in 
research and education, and sponsors must examine the possibility of developing 
new endpoints and outcome assessments for use in clinical trials.
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objeCtives: To explore the potential of online patient networks (PN) as a viable 
source of PRO data for clinical research. Several PNs have emerged in the last few 
years in different European countries, and as a natural meeting point for chronic 
patients with an active engaged with their communities, they represent a promising 
source of patient reported data. In this original, the experience with the French PN 
“Carenity” is described. Methods: Given the great heterogeneity of the users of 
“Carenity”, and the fact that the test was computer-led by definition, a Computer 
Adaptive Test (CAT) was considered the best choice. The authors decided to use a 
culturally adapted version of CAT-Health system, which measures generic health-
related quality of life (HRQoL). However, in absence of a calibration for the French 
population, a selection of the best items was used, using the Spanish calibration 
as a reference. All patients in the PN were invited to participate in the test. A score 
was estimated for the test using the Spanish parameters, as a rough approxima-
tion of the real score. Age, sex and the main pathology of the subjects were also 
collected. Results: Preliminary results from the first week of data collection show 
601 patients answered (Women: 404, Men: 140). The most frequent reported patholo-
gies and their t-scores were multiple sclerosis (N:92,M:37.91,SD:5.85), fibromyalgia 
(N:81,M:36.65,SD:4.99), ankylosing spondylitis(N:60,M:37.74,SD:5.32) and both types 
of diabetes (I: N:53,M:50.38,SD:10.94, II: N:41,M:48.12,SD:10.04). Significant differ-
ences (p< 0.05) were found in diabetes patients by sex, and between both types 
of diabetes and the other 3 most common pathologies. ConClusions: Carenity 
PN seems to be a fast way to obtain PRO scores directly from patients. Preliminary 
results show differences in the expected direction.
ReseaRCh on Methods – statistical Methods
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objeCtives: Late phase research is conducted outside the RCT setting where there 
is uncertainty as to how many subjects are needed to find differences between 
groups. Due to the lack of real-world information (non-RCT) in late phase designs, 
there are no tangible inputs for power calculations. This research defines a bias-free 
method to examine data while determining sample size. Methods: As an example 
of the application of a DPP, a study examining the decrease of HGbA1c values in two 
different insulin delivery methods was examined in patients with several comor-
bid conditions. Literature examined found little to no data and a DPP was used to 
determine effect size (ES) and standard deviations (SDs) once 30 patients had been 
enrolled in each group. The DPP procedure was: 1) Determine the test statistic; 2) 
Identify the power formula most appropriate to the test statistic; 3) Determine the 
ES, variation and assumptions needed for the data-peek in the form required by the 
formula; 4) Construct a matrix of possible sample size values; and 5) Select a sample 
size that is obtainable and answers the research question. Results: Data for group 
A demonstrated a mean reduction of 2.75% ±0.760, group B mean reduction of 3.01% 
±0.636. Exact power analysis showed 113 subjects per group would be needed. A 
